Cardio Diagnostics (CDIO) Holdings and AGEPHA Pharma announced an agreement that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease. AGEPHA Pharma will supply its FDA-approved anti-inflammatory medication, LODOCO, for a Cardio Diagnostics-sponsored clinical study. The study will explore the use of Cardio Diagnostics’ PrecisionCHD test to identify patients with inflammation-driven CHD and assess their response to LODOCO.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDIO: